Title:
B7H3-TARGETED GAMMA DELTA T CELL MODULATION
Document Type and Number:
WIPO Patent Application WO/2024/006907
Kind Code:
A3
Abstract:
The current disclosure relates to, inter alia, compositions and methods, e.g., immunotherapies for cancer and autoimmunity. The present compositions comprise heterodimeric proteins comprising an alpha chain and a beta chain, each of the alpha chain and the beta chain comprising a portion of butyrophilin BTN2A1 and/or BTN3A1 adjoined via a linker to a targeting domain directed to B7H3.
Inventors:
SCHREIBER TAYLOR (US)
DE SILVA SURESH (US)
FROMM GEORGE (US)
LAI ANNE (US)
FRANKLIN DEREK (US)
DE SILVA SURESH (US)
FROMM GEORGE (US)
LAI ANNE (US)
FRANKLIN DEREK (US)
Application Number:
PCT/US2023/069372
Publication Date:
February 15, 2024
Filing Date:
June 29, 2023
Export Citation:
Assignee:
SHATTUCK LABS INC (US)
International Classes:
C07K16/28; A61K38/00; C07K14/00; C07K19/00; A61P35/00; C12N15/09
Domestic Patent References:
| WO2022093310A1 | 2022-05-05 |
Foreign References:
| US20200216505A1 | 2020-07-09 |
Attorney, Agent or Firm:
ALTIERI, Stephen, L. et al. (US)
Download PDF:
Previous Patent: BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS
Next Patent: ENRICHMENT OF ABERRANTLY METHYLATED DNA
Next Patent: ENRICHMENT OF ABERRANTLY METHYLATED DNA